News

Vittamed Corporation will exhibit at the 2016 AANS meeting in Chicago

Vittamed, a neurodiagnostic and monitoring company that has developed an innovative, non-invasive system to measure intracranial pressure, will attend the 84th American Association of Neurological Surgeons (AANS) meeting.  The trade show is being held at McCormick Place in Chicago, IL, April 30 – May 4, 2016.  Vittamed can be found at booth # 4136, where we will showcase our Vittamed 205 ICP system.  AANS being one of the largest trade shows for neurosurgeons, Vittamed is very excited to be exhibiting this year.  Please stop by our booth to learn more about the Vittamed 205.

 

Vittamed secures $10M in venture funding for commercialization of non-invasive Intracranial Pressure (ICP) system

BOSTONOct. 16, 2015 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostic company that has developed a novel non-invasive intracranial pressure monitor announced that it has secured $10M in Series A financing by Xeraya Capital Labuan Ltd ("Xeraya Capital") via a special purpose vehicle led the investment round (committed $8M) with additional commitment from an existing investor Imprimatur Capital and other investors. The funding will support product launch in EuropeAustralia, and other countries, a 510k submission to the FDA, and commercialization in the US.

Full Text: PRNewswire

 

American and German Space Institutes used Vittamed's  Non-invasive intracranial pressure meter (Vittamed 205) in Trail Blazing Biomedical Research Study

HOUSTON, June 30, 2015 /PRNewswire-USNewswire/ -- The National Space Biomedical Research Institute (NSBRI) announced today that a pathfinder study is underway in Cologne, Germany to investigate the effects of simulated spaceflight conditions on brain physiology.

More info...

Visit us at 1st Congress of the European Academy of Neurology, June 20-23, Berlin (Germany), stand D55.

Vittamed will present the "Vittamed 205" - the first non-invasive ICP meter capable of accurately, precisely and reliably measuring the absolute value of intracranial pressure (ICP) without the need for periodic calibration to the individual patient and the „Vittamed 505“ - non-invasive cerebrovascular autoregulation monitor, which offers the non-invasive technique of continuously and non-invasively monitoring the cerebrovascular autoregulation dynamics in real time.

More info: http://www.eaneurology.org/berlin2015/

Visit us at 83th AANS Annual Scientific, May 2-6, 2015, Washington, D.C. Stand 630.

Vittamed will present the "Vittamed 205" - the first non-invasive ICP meter capable of accurately, precisely and reliably measuring the absolute value of intracranial pressure (ICP) without the need for periodic calibration to the individual patient.

More info: http://www.aans.org/annualmeeting.aspx

Visit us at Medical World Americas Conference and Expo, April 27-29, 2015, George R. Brown Convention Center, Houston,TX, Stand 425.

Vittamed will present the "Vittamed 205" - the first non-invasive ICP meter capable of accurately, precisely and reliably measuring the absolute value of intracranial pressure (ICP) without the need for periodic calibration to the individual patient.

More info: http://medicalworldamericas.com

Vittamed will participate in one of the biggest Neurosurgery Congresses - 14th Asian Australasian Congress of Neurological Surgeons on 15-18 April, 2015 in South Korea. Visit us at Stand E17.

UAB “Vittamed”, a neurodiagnostics medical device company from Kaunas, Lithuania will exhibit in one of the biggest Neurosurgery Congresses - 14th Asian Australasian Congress of Neurological Surgeons on 15-18 April, 2015 in South Korea.

Vittamed's exhibition at "14th Asian Australasian Congress of Neurological Surgeons " is funded by European Union structural funds programme "New Opportunities " - "Increasing business productivity and improving business environment".

Vittamed will present the "Vittamed 205" - the first non-invasive ICP meter capable of accurately, precisely and reliably measuring the absolute value of intracranial pressure (ICP) without the need for periodic calibration to the individual patient and the „Vittamed 505“ - non-invasive cerebrovascular autoregulation monitor, which offers the non-invasive technique of continuously and non-invasively monitoring the cerebrovascular autoregulation dynamics in real time.

More info: http://aacns2015.com

Visit us at 2nd annual MedTech & Diagnostics Innovations Summit, 13th November 2014 • Hotel Nikko Düsseldorf• Germany

October 22, 2014

The 2nd Annual MedTech & Diagnostics Innovations Summit is once again being held to coincide with the leading annual international tradeshow Medica with its anticipated 135,000 visitors. The Summit is designed to bring together a specialist audience from leading and growth companies focused on M+A, alliances and Investment. The program will feature keynotes from industry leaders and plenary panels on industry acquisitions; public markets, venture investment and growth, company finance, connected health, device and diagnostics. The subjects of regulation and reimbursement will also be covered.

Apart from the plenary session the program will also feature 20+ public and private company presentations focused on innovation and alliances/investment opportunities. The MedTech and Device companies track will cover; Oncology, Cardiovascular, Imaging, Surgical Devices & Implants. There will be a separate track for diagnostics. These will be held in 2 parallel streams.

There will be many networking opportunities. There is a 1-to-1 online meeting system with meeting rooms provided.

Vittamed's exhibition at "Medtech& Diagnostics innovation summit" is funded by European Union structural funds programme "New Opportunities " - "Increasing
business productivity and improving business environment".

More info at: Sachsforum.com

Vittamed's CEO Remis Bistras has received Covidien presentation scholarship and was chosen to present at AdvaMed 2014 conference in Chicago, October 7th, 2014 

October 6, 2014

The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems.

AdvaMed members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.

More info at: AdvaMed 2014

Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors

Boston, MA – August 29, 2014

Vittamed Corporation, a neurodiagnostics medical device company based in Boston announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd  was appointed to the company’s Board of Directors.

Full text: Article

Clinical study „Update in intracranial pressure evaluation methods and translaminar pressure gradient role in glaucoma“ was published in the Journal of  "Acta Ophthalmologica". Vittamed‘s non-invasive absolute ICP value meter was used as a key technology for this research.

August 11, 2014

The study results confirmed CSF (cerebrospinal fluid) pressure as translaminar counter pressure against IOP (intraocular pressure) to be of major importance in glaucoma, and future investigations are needed to elucidate the involvement of CSF pressure and its fluctuations in the development, progression and management of glaucoma.

More info at: Wiley online library

Press Release: Vittamed Received CE Mark Approval for Non-invasive Intracranial Pressure Meter and Non-invasive Cerebrovascular Autoregulation Monitor

July 23, 2014

"CE approval for both devices is not only an important milestone for our company as we move toward commercialization but also an important advance in patient care," stated  Dr. Remis Bistras, the CEO of Vittamed.  "Invasive options for intracranial pressure measurement and for cerebral perfusion monitoring have historically been limited by risk, inconvenience, and high costs. Our monitors, in contrast, add no material risk. They are totally non-invasive and may be deployed routinely whenever and wherever indicated, including the outpatient setting. " Full text...

Full text: PRNewswire

Vittamed's CEO Remis Bistras will present at the IN3 Medical device 360o in Boston on June 19-20, 2014. 

June 9, 2014

More info at: IN3 Medical device 360o

New clinical study finds Vittamed’s non-invasive Intracranial Pressure measurement technology a significant improvement over existing methods

May 27, 2014

The study, published in the scientific journal Neurological Research, found Vittamed’s non-invasive intracranial pressure (ICP) measurement method based on ultrasound technology to have better diagnostic reliability on neurological patients (as measured by both sensitivity and specificity) than the optic nerve sheath diameter (ONSD) method for detecting elevated intracranial pressure.Full text...

Clinical stady at Neurological Research Journal

Clinical study „The Difference in Translaminar Pressure Gradient and Neuroretinal Rim Area in Glaucoma and Healthy Subjects“ was published in the Journal of  the Ophthalmology. Vittamed‘s non-invasive absolute ICP value meter was used as a key technology for this research.

The study results confirmed previous findings (using invasive ICP assessment) and demonstrated, that translaminar pressure gradient was higher in glaucoma patients than in healthy controls. Reduction of neuroretinal rim area was related to higher TPG in normal tension glaucoma patients. The study confirmed the idea that decreased ICP could result in an increased TPG and lead to glaucomatous damage.

More info at: Hindawi Publishing

Vittamed's CEO Remis Bistras participated at the Neurotech Investing and Partnering Conference in Boston April 23-24, 2014

The premier partnering and investing conference for the neurotechnology industry including pharmaceuticals, medical devices and diagnostics will be held Wednesday and Thursday, April 23-24, 2014 at the Ritz-Carlton in Boston. 

More info at: the Neurotech Investing and Partnering

Vittamed's CEO Remis Bistras presented at the American Association of Neurological Surgeons (AANS) Annual meeting in San Francisco, April 5-9, 2014.

Founded in 1931, the American Association of Neurological Surgeons (AANS) is a scientific and educational association with over 8,000 members worldwide. The AANS is dedicated to advancing the specialty of neurological surgery in order to provide the highest quality of neurosurgical care to the public.
More info at: AANS

Vittamed to Present at OneMedForum in San Francisco, January 14, 2014

Vittamed’s CEO Remis Bistras will speak at the 7th Annual OneMedForum San Francisco be held at Westin Hotel,  on January 14, 2013 at 2:45pm.

More info at: One Med Forum SF2014

Bio-News Texas about Vittamed: NBCM Scientists Research New Non-invasive Intracranial Pressure Measurement Device In Patients And Potentially Astronauts 

Two Baylor College of Medicine scientists are leaders of a clinical research study of a non-invasive intracranial pressure measurement device launched by the National Space Biomedical Research Institute (NSBRI) and the device’s developer Vittamed Corporation. The study will include the monitoring of neurological patients, as a prelude to possible future use with astronauts. ...Full text

Source: Bio News Texas

Medical Device Daily: NSBRI evaluates use of Vittamed's intracranial pressure monitor

By Omar Ford

A problem that some astronauts face is the development of serious visual impairment conditions that are associated symptoms suggestive of elevated pressure on the brain, or increased intracranial pressure. This has prompted the National Space Biomedical Research Institute (NSBRI), a non-profit organization that is funded by NASA to partner withVittamed (Boston), a med-tech firm that has developed a device to could non-invasively measure absolute intracranial pressure (ICP), to initiate a clinical research study..Full text

Source: Medical Device Daily

Press Release: New non-invasive intracranial pressure measurement device used to assess elevated brain pressure in patients may also benefit astronauts. Boston - Dec. 18, 2013

A clinical research study of a non-invasive intracranial pressure measurement device has been launched by the National Space Biomedical Research Institute (NSBRI) and Vittamed Corporation, the developer of the device. The study will include the monitoring of neurological patients, as a prelude to possible future use with astronauts. ... Full text

Full text: Reuters

Vittamed's CEO Remis Bistras will present at the New England Venture Summit in Boston on December 11, 2013

The 8th annual New England Venture Summit is the premier industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of early stage and emerging growth companies, university researchers, incubators and premier service providers.

More info at: The New England Venture Summit 2013

Vittamed's non-invasive absolute Intracranial Pressure (aICP) value meter, non-invasive cerebrovascular autoregulation monitor and non-invasive intracranial pressure and volume wave monitoring system was presented in 15th International Conference on Intracranial pressure and Brain monitoring, Singapore,  6-10 November 2013

  

More info at: ICP2013

Visit us at 15th International Conference on Intracranial pressure and Brain monitoring, Singapore,  6-10 November 2013

The International Conference on Intracranial Pressure and Brain Monitoring is a scientific and academic conference focusing on the importance of neuro-monitoring and management in diseases of the central nervous system. In trauma, stroke, hemorrhage and during the administration of anesthesia, monitoring of intracranial pressure is of importance and its control has significant effects on the patient’s outcome.

More info at: ICP2013

Vittamed's CEO Remis Bistras will present at the leading Massachusetts Medical Device Industry Council (MassMEDIC) Investors conference in Boston on November 1, 2013

MassMEDIC’s annual showcase of emerging medtech companies from around the New England region. Program will also include presentations by five public medtech companies and plenary presentations.

More info at: MassMedic

Vittamed was selected to present at AdvaMed 2013 Conference in Washington D.C.

AdvaMed 2013 is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities, and networking. 

More info at: AdvaMed 2013

Vittamed is invited to present at Medtech Partnering and Investment conference "Medical Device 360" in Boston on June 26th

This is a premier Medtech partnering event and we are pleased to present our non-invasive neurodiagnostic and monitoring technology to Venture Capital community and major medtech corporations. 

More info at: "Medical Device 360" Boston

Euronews about non-invasive intracranial pressure monitoring (the European Commission Brainsafe project)

Copyright © European Commission 2013 / euronews 2013

Clinical studies - non-invasive intracranial pressure monitoring

Measuring intracranial pressure non-invasively - clinical testing

Statistically significant scientific results of independent prospective comparative clinical study of  Vittamed‘s non-invasive absolute ICP value measurement technology are already published in Neurology (Official Journal of the American Academy of Neurology) 2012 May 22;78(21): 1684-91.
Assessment of non-invasive ICP meter created by the European Commission‘s FP7 project BrainSafe together with Kaunas University of Technology shows clinically acceptable accuracy and precision of Vittamed‘s non-invasive ICP value measurement method and confirms that this method does not need a patient specific calibration.

Full clinical stady at: Neurology

The excellent EC Research Executive Agency’s evaluation of  Vittamed’s EC FP7 project Brainsafe. March 27, 2012

Vittamed’s project Brainsafe was favorably evaluated by European commission’s Research Executive Agency (REA). According to REA the project has been expertly run with great achievement of objectives. The quality of the science and engineering is excellent and the developed technology certainly raises the state-of-the art in this area and has potential for major impact in the intensive care as well as a number of related neurological fields. The Brainsafe non-invasive absolute intracranial pressure measurement device based on two-depth Doppler ultrasound technology has a potential to be a break through technology and is expected to be widely used in the field. 

More info at: Brainsafe description

Vittamed's non-invasive absolute Intracranial Pressure (aICP) technology was presented in European Congress of Neurosurgery, Rome, October 9-14, 2011

Vittamed has presented it‘s recent atchievements and technology testing results in European Congress of Neurosurgery, Rome, October 9-14, 2011. EANS 2011 provided specialists in neurosurgery, neuroscience and neurology with a unique opportunity to gather the latest information on relevant topics in the field, including vascular neurosurgery.

More info at: EANS 2011

The non-invasive ICP measurement technology was presented in Neuro Talk 2011, the dedicated event for global neuroscientists, May 22-25, 2011 Dalian, China

The BIT's 2nd Annual World Congress of NeuroTalk-2011 was jointly held with BIT's 4th World Cancer Congress in Dalian, China. There were more than 300 participants from more than 36 countries and areas. Participants from academic comunity, industrial professionals and key-decision makers delivered the new achievement on their research, together discussed and analysed the latest development.

More info at BIT's 2nd Annual World Congress of Neuro Talk 2011.